Home Page

DUBLIN, Dec. 14, 2018 /PRNewswire/ --

The "Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, etc.) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis test solution/diagnosis market is projected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period.

This market is primarily driven by factors such as the high burden of hepatitis worldwide, the increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives. Emerging markets such as China, India, Brazil, and Africa are expected to offer lucrative growth opportunities for the players in this market. However, the high cost of NAT tests and a lack of mandate for NAT in developing countries are expected to restrain the growth of this market during the forecast period.

The ELISA segment is expected to account for the largest share of the global hepatitis test solution/diagnosis market, by technology. The large share of ELISA is mainly driven by the wide acceptance of this test in clinical practices to diagnose hepatitis. Rapid diagnostics test segment is expected to register the highest CAGR during the forecast period. High growth of rapid diagnostics test segment can be attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

The hospital and diagnostics laboratories segment is expected to account for the largest share of hepatitis test solution/diagnosis market, by end user, in 2018 and is expected to register the highest CAGR during the forecast period. This can primarily be attributed to the growing patient population, increase in Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests.

Geographically, the hepatitis test solution/diagnosis market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018 North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market. The large share of the North America region is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.

The APAC region is projected to grow at the highest CAGR during the forecast period. The growth of the hepatitis test solution/diagnosis market in this region is driven by the widespread prevalence of hepatitis infections, increased healthcare spending by a larger population base, and modernization of healthcare infrastructure.

Nucleic Acid Tests (NATs) are relatively more expensive hepatitis diagnostic techniques than ELISA tests as the cost of NAT instruments is higher, in terms of outright purchases as well as rental agreements. NAT instruments require heavy investments, which most blood banks cannot afford. As a result, most end users opt for ELISA (serology) testing for hepatitis diagnosis, which limits the growth of the hepatitis testing market to a certain extent.

The key players in the hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMrieux (France), and Grifols (Spain)

Key Topics Covered:

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Market Scope
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Primary Data
2.2 Secondary Data
2.3 Key Data From Secondary Sources
2.4 Market Size Estimation
2.5 Market Breakdown And Data Triangulation

3 Executive Summary

4 Premium Insights
4.1 Hepatitis Testing: Market Overview
4.2 Geographic Analysis: Hepatitis Testing Market, By Disease Type (2018)
4.3 Hepatitis Testing Market, By Technology, 2018 Vs. 2023
4.4 Hepatitis Testing Market, By End User, 2016-2023

5 Market Overview
5.1 Introduction
5.1.1 Drivers
5.1.1.1 High Burden Of Hepatitis
5.1.1.2 Increasing Blood Transfusion And Donations
5.1.1.3 Benefits Of Poc Instruments & Kits
5.1.1.4 Awareness Initiatives
5.1.2 Restraints
5.1.2.1 High Cost Of NAT
5.1.2.2 Lack Of Mandate For Nat In Developing Countries
5.1.3 Opportunities
5.1.3.1 Emerging Markets

6 Hepatitis Testing Market, By Disease Type
6.1 Introduction
6.2 Hepatitis B (HBV)
6.3 Hepatitis C (HCV)
6.4 Other Hepatitis Diseases

7 Hepatitis Testing Market, By Technology
7.1 Introduction
7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
7.3 Rapid Diagnostic Tests (RDT)
7.4 Polymerase Chain Reaction (PCR)
7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.6 Other Technologies

8 Hepatitis Testing Market, By End User
8.1 Introduction
8.2 Hospital & Diagnostic Laboratories
8.3 Blood Banks
8.4 Other End Users

9 Hepatitis Testing Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Rest Of Europe
9.4 Asia Pacific
9.5 Rest Of The World

10 Competitive Landscape
10.1 Market Overview
10.2 Market Ranking Analysis, 2017
10.3 Competitive Situation And Trends
10.3.1 Collaborations, Agreements, And Partnerships
10.3.2 Product Launches And Approvals
10.3.3 Acquisitions

11 Company Profiles
11.1 Abbott Laboratories, Inc.
11.2 Roche Diagnostics
11.3 Bio-Rad Laboratories
11.4 Siemens Healthineers
11.5 Diasorin
11.6 Qiagen
11.7 Danaher Corporation
11.8 Grifols
11.9 Biomrieux SA
11.10 Ortho Clinical Diagnostics (A Part Of The Carlyle Group)
11.11 Fujirebio, Inc. (A Part Of Miraca Group)

For more information about this report visit https://www.researchandmarkets.com/research/schk9b/global_hepatitis?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-hepatitis-test-solutiondiagnosis-market-to-2023-with-roche-abbott-laboratories-bio-rad-siemens-diasorin-qiagen-danaher-biomrieux-and-grifols-dominating-300765668.html

SOURCE Research and Markets